Open access · CC-BY
via OpenAlex
Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial
Takeshi Osonoi, Shinichiro Shirabe, Miyoko Saito, Mitsuru Hosoya, Satako Douguchi, Kensuke Ofuchi, Makoto Katoh
Frontiers in Pharmacology · 2023 · ▲ 4 citations
Abstract
Background: Imeglimin is a novel type 2 diabetes (T2D) drug that is expected to improve mitochondrial function. In its phase 3 clinical trials in Japanese patients with T2D, the hemoglobin A1c (HbA1c) decrease following imeglimin administration was slow, reaching a plateau after 20–24 weeks of treatment. In general, the erythrocyte lifespan may be a factor when HbA1c shows an abnormal value. Therefore, this study will comparatively evaluate HbA1c and other markers of glycemic control in patients with T2D after imeglimin administration and also examine the effects of imeglimin on erythrocytes. Methods: This single-arm, open-label, prospective, exploratory study is designed to evaluate the divergence between HbA1c and glycoalbumin (GA) or 1,5-anhydroglucitol (1,5-AG) and the glycemic reduction rate in 30 patients with T2D with inadequate glycemic control when imeglimin 2,000 mg is administered for 6 months. In addition, we will examine the effect on erythrocytes, the presumed cause of this divergence. We will measure sustained glycemic variability using flash glucose monitoring and examine the relationship between changes in these indices and HbA1c. Moreover, because prolonged erythrocyte lifespan is a possible cause of falsely high HbA1c levels, erythrocyte lifespan, erythrocyte deformability, and hemoglobin concentration will be evaluated as effects of imeglimin on erythrocytes. Furthermore, if imeglimin has an ameliorative effect on erythrocyte deformability, it may improve peripheral arterial disease; thus, we will also evaluate the toe-brachial pressure index, a measure of this effect. Discussion: In this study, if imeglimin administration results in diverging rates of hypoglycemic effect between HbA1c and GA or 1,5-AG and prolongs erythrocyte lifespan, GA and 1,5-AG, rather than HbA1c, will be considered appropriate measures of the hypoglycemic effect in the early stages of imeglimin administration. If imeglimin improves erythrocyte deformability, it may also be a new treatment strategy for peripheral arterial disease, a chronic complication of T2D. Ethics and dissemination: The study protocol was scientifically and ethically reviewed and approved by the Certified Clinical Research Review Board of Toho University (approval number: THU22002). The study protocol was registered in the Japan Registry of Clinical Trials (jRCT) in December 2022 (jRCTs031220489).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fphar.2023.1205021
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Osonoi, T., Shirabe, S., Saito, M., Hosoya, M., Douguchi, S., Ofuchi, K., & Katoh, M. (2023). Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial. <em>Frontiers in Pharmacology</em>. https://doi.org/10.3389/fphar.2023.1205021
Vancouver
Osonoi T, Shirabe S, Saito M, Hosoya M, Douguchi S, Ofuchi K, et al. Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial. Frontiers in Pharmacology. 2023. doi:10.3389/fphar.2023.1205021.
BibTeX
@article{takeshi2023Compar,
title = {Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial},
author = {Takeshi Osonoi and Shinichiro Shirabe and Miyoko Saito and Mitsuru Hosoya and Satako Douguchi and Kensuke Ofuchi and Makoto Katoh},
journal = {Frontiers in Pharmacology},
year = {2023},
doi = {10.3389/fphar.2023.1205021},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Endocrinology 2025
Open access · CC-BY
Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial
Merry, Graham, M.D. 2009
Open access · US-GOV
A Pilot Study to Evaluate Clinical Outcomes of Photobiomodulation in Patients With Age Related Macular Degeneration of the Dry Type.
Diabetes Mellitus 2020
Open access · CC-BY
1,5-anhydroglucitol in diabetes: its role in diagnostics, screening, glycemic status assessment, and the prediction of complications
University of Milano Bicocca 2020
Open access · US-GOV
Relationship Between Frailty and Clinical Outcomes in Elderly Patients With COVID-19
Сахарный диабет 2020
Citation only
1,5-ангидроглюцитол при сахарном диабете: роль в диагностике, скрининге, оценке гликемического статуса и прогнозе осложнений
University Hospital of Ferrara 2024
Open access · US-GOV